Bellerophon Therapeutics, Inc.Bellerophon Therapeutics, Inc.Bellerophon Therapeutics, Inc.

Bellerophon Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪716.83 K‬USD
−0.8247USD
‪−19.83 M‬USD
‪11.79 M‬
Beta (1Y)
2.20

About Bellerophon Therapeutics, Inc.

CEO
Craig R. Jalbert
Headquarters
Warren
Employees (FY)
18
Founded
2009
FIGI
BBG007X1TKD5
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BLPH is 0.0545 USD — it has increased by 0.74% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Bellerophon Therapeutics, Inc. stocks are traded under the ticker BLPH.
Bellerophon Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
BLPH stock is 0.73% volatile and has beta coefficient of 2.20. Check out the list of the most volatile stocks — is Bellerophon Therapeutics, Inc. there?
BLPH earnings for the last quarter are 0.27 USD per share, whereas the estimation was −0.49 USD resulting in a 155.10% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Bellerophon Therapeutics, Inc. earnings.
Yes, you can track Bellerophon Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
BLPH stock has fallen by 4.72% compared to the previous week, the month change is a 0.55% rise, over the last year Bellerophon Therapeutics, Inc. has showed a 99.25% decrease.
BLPH net income for the last quarter is ‪−1.92 M‬ USD, while the quarter before that showed ‪−5.14 M‬ USD of net income which accounts for 62.61% change. Track more Bellerophon Therapeutics, Inc. financial stats to get the full picture.
Today Bellerophon Therapeutics, Inc. has the market capitalization of ‪661.78 K‬, it has decreased by 6.24% over the last week.
No, BLPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BLPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bellerophon Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
BLPH reached its all-time high on Feb 27, 2015 with the price of 193.8000 USD, and its all-time low was 0.0290 USD and was reached on Nov 17, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 18.00 employees. See our rating of the largest employees — is Bellerophon Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bellerophon Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bellerophon Therapeutics, Inc. stock shows the sell signal. See more of Bellerophon Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.